News

In the bacterial endotoxin test using the gel clot Limulus Amebocyte Lysate (LAL) assay, the Maximum Valid Dilution (MVD)​ is a critical calculated parameter. Its importance is multifaceted.

In the Saudi Food and Drug Authority (SFDA) regulatory framework, bacterial endotoxin control has become an essential requirement for many medical devices intended for clinical use in Saudi Arabia. Products that directly contact blood circulation, damaged tissue, or sterile body cavities must demonstrate strict compliance with international biocompatibility and sterility standards.

With the rapid advancement of the biopharmaceutical and medical device industries, the Recombinant Factor C (rFC) endotoxin detection method has emerged as an important extension and sustainable alternative to traditional Limulus Amebocyte Lysate (LAL) reagents. Owing to its non-animal origin, high specificity, and superior lot-to-lot consistency, rFC offers significant technical and ecological advantages.

The primary objective of Bacterial Endotoxin Testing (BET) is to control the risk of pyrogens in pharmaceutical products and to prevent serious adverse reactions in humans, such as fever and shock. According to major pharmacopoeial standards, including the United States Pharmacopeia (USP) and the European Pharmacopoeia (Ph. Eur.), medicinal products that directly enter the bloodstream, come into contact with mucous membranes or damaged tissues, or are used in surgical or implantable procedures are subject to mandatory endotoxin testing.

The safety of parenteral medicines and medical devices is heavily dependent on the rigorous detection of bacterial endotoxins, which can cause severe pyrogenic reactions if present in released products. 

BETMAT Biotechnology is committed to advancing bacterial endotoxin testing (BET) through innovative, animal-free technologies that meet the highest global standards of safety and scientific integrity. The publication of the United States Pharmacopeia (USP) Chapter <86>, “Bacterial Endotoxins Test Using Recombinant Reagents”, marks a significant step forward in the modernization of endotoxin testing methodologies.

The primary objective of Bacterial Endotoxin Testing (BET) is to control the risk of pyrogens in pharmaceutical products and to prevent serious adverse reactions in humans, such as fever and shock. According to major pharmacopoeial standards, including the United States Pharmacopeia (USP) and the European Pharmacopoeia (Ph. Eur.), medicinal products that directly enter the bloodstream, come into contact with mucous membranes or damaged tissues, or are used in surgical or implantable procedures are subject to mandatory endotoxin testing.

In the performance of bacterial endotoxin test (BET) assays, essential depyrogenated supplies include endotoxin-free water, endotoxin-free glass test tubes, pyrogen-free pipette tips, pyrogen-free microplates, and endotoxin-free sample bottles. All aforementioned items are critical for ensuring assay accuracy, as depyrogenation is a mandatory requirement for BET-related materials.

The kinetic chromogenic LAL assay is a fully compendial, quantitative bacterial endotoxin testing (BET) method widely adopted globally across medical devices, parenteral pharmaceuticals, biologics, and advanced therapies. It is recognized by USP <85>, EP 2.6.14, CP1143, JP 4.01, and WHO guidelines as an equivalent alternative to gel-clot and turbidimetric methods, with increasing preference for its quantitative precision, high sensitivity ( 0.005 EU/mL, even 0.001EU/ml ), and automation capabilities.

Key Characteristics & Classification of LAL Reagents